Definium Therapeutics, Inc.
DFTX
Peringkat dalam Saham
#3484
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Harga Saham
$35.98
Kapitalisasi Pasar
$4.83B
Perubahan (1 hari)
1.39%
Perubahan (1 tahun)
239.49%
Negara
US
Perdagangan Definium Therapeutics, Inc. (DFTX)
Kategori
Healthcare
Riwayat harga saham Definium Therapeutics, Inc. (DFTX)
Harga penutupan tertinggi: $10.57 pada 2024-04-01
Harga penutupan terendah: $4.87 pada 2020-03-01
Harga penutupan terendah: $4.87 pada 2020-03-01
Riwayat harga saham Definium Therapeutics, Inc. dari 2020 hingga 2026
Performa harga saham tahunan
| Tahun | Performa |
|---|---|
| 2024 | 205.04% |
| 2023 | 33.53% |
| 2022 | -89.94% |
| 2021 | -40.17% |
| 2020 | 0.00% |
Harga saham perusahaan atau pesaing serupa
| Perusahaan | Harga saham | Perubahan 1th% | Negara |
|---|---|---|---|
| $535.81 | 25.65% |
US
|
|
| $188.41 | 601.69% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $890.95 | 9.43% |
NL
|
